Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

49.99 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >
3 Russell 2000 Stocks We Think Twice About
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?
Over the last six months, Haemonetics’s shares have sunk to $51.21, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 24.4% gain. This might have investors contemplating their... 
Via StockStory
Topics Stocks Supply Chain
3 Healthcare Stocks We Find Risky
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
Unpacking Q2 Earnings: Haemonetics (NYSE:HAE) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - specialty... 
Via StockStory
9 Analysts Have This To Say About Haemonetics
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Medical Devices & Supplies - Specialty Stocks Q2 Results: Benchmarking Haemonetics (NYSE:HAE)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - specialty... 
Via StockStory
1 Stock Under $50 to Own for Decades and 2 Facing Headwinds
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
How Do Investors Really Feel About Haemonetics Corp?
 
Via Benzinga
Dentsply Sirona, Acadia Healthcare, and Haemonetics Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics Economy Government World Trade
1 of Wall Street’s Favorite Stock on Our Buy List and 2 We Avoid
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
What's Driving the Market Sentiment Around Haemonetics?
 
Via Benzinga
1 Profitable Stock for Long-Term Investors and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
3 Out-of-Favor Stocks We Keep Off Our Radar
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. 
Via StockStory
Topics Firearms
Sherwin-Williams, Sealed Air, Super Micro, Globus Medical, and Haemonetics Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics ETFs Economy
1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
3 Cash-Producing Stocks with Open Questions
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
HAE Q2 Deep Dive: Margin Expansion Amid Revenue Decline and Product Execution Challenges
Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 4.4% year on year to $321.4 million. Its non-GAAP profit of $1.10 per share was... 
Via StockStory
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
 
Via Benzinga
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Haemonetics Through 6 Analysts
 
Via Benzinga
Haemonetics (NYSE:HAE) Surprises With Strong Q2 But Stock Drops 24%
Blood products company Haemonetics (NYSE:HAE). reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 4.4% year on year to $321.4 million. Its non-GAAP profit of $1.10... 
Via StockStory
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Haemonetics (HAE) Q1 Revenue Falls 4%
Via The Motley Fool
Peering Into Haemonetics's Recent Short Interest
 
Via Benzinga
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect
Blood products company Haemonetics (NYSE:HAE). will be reporting results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics World Trade
Peering Into Haemonetics's Recent Short Interest
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.